HONG KONG,Nov. 29,2024 -- Akeso,Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce its participation in the upcoming 7th Annual Evercore HealthCONx Conference and Citi 2024 Global Healthcare Conference,both taking place in Miami.

Akeso will participate in a fireside chat at the 7th Annual Evercore HealthCONx Conference on Wednesday,December 4,2024,at 8:45 AM ET. Akeso will also join a fireside chat at the Citi 2024 Global Healthcare Conference on Thursday,December 5,from 8:45 AM to 9:25 AM ET.

Live streams of Akeso's presentations at the 7th Annual Evercore HealthCONx Conference will be available at:https://wsw.com/webcast/evercore44/9926.hk/2446353

About Akeso

Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research,development,manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012,the company has created a unique integrated R&D innovation system with the comprehensive end-to-end drug development platform (ACE Platform) and bi-specific antibody drug development technology (Tetrabody) as the core,a GMP-compliant manufacturing system and a commercialization system with an advanced operation mode,and has gradually developed into a globally competitive biopharmaceutical company focused on innovative solutions. With fully integrated multi-functional platform,Akeso is internally working on a robust pipeline of over 50 innovative assets in the fields of cancer,autoimmune disease,inflammation,metabolic disease and other major diseases. Among them,22 candidates have entered clinical trials (including 11 bispecific/multispecific antibodies and bispecific antibody-drug conjugates). Additionally,5 new drugs are commercially available,and 5 new drugs across 7 indications are currently under regulatory review for approval. Through efficient and breakthrough R&D innovation,Akeso always integrates superior global resources,develops the first-in-class and best-in-class new drugs,provides affordable therapeutic antibodies for patients worldwide,and continuously creates more commercial and social values to become a global leading biopharmaceutical enterprise.

For more information,please visithttps://www.akesobio.com/en/about-us/corporate-profile/and follow us onLinkedin,andX(formerly Twitter).